Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

作者：Guoming Shi, Xiaoyong Huang, Xiaowu Li, Fei Liang, Qiang Gao, Daohan Zhang, Jia‐Cheng Lu, Yuan Ji, Zhiqiang Hu, Yi Chen, Shuang‐Jian Qiu, Yong Yi, Xiaodong Zhu, Hui‐Chuan Sun, Yinghong Shi, MinJie Peng, Xiaoying Wang, Cheng Huang, Zhen‐Bin Ding, Yifeng He, Ying-Hao Shen, Yongfeng Xu, Yong‐Sheng Xiao, Jie Hu, Jian Zhou, Jia Fan · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00376-6 · 被引用次数：20 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Gallbladder and Bile Duct Disorders、Liver Diseases and Immunity